Saxena White P.A. is pleased to announce that on November 21, 2025, the United States District Court for the Northern District of California appointed Shuo-Hsien Wang as Lead Plaintiff and Saxena White P.A. as Lead Counsel for the derivatives class in the securities class action against Hims & Hers Health, Inc. (“Hims” or the “Company”), its Chief Executive Officer Andrew Dudum, and its Chief Financial Officer Oluyemi Okupe (collectively, “Defendants”).

The action alleges that, between April 29, 2025 and June 23, 2025 (the class period), Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business and operations, including its long-term collaboration with Novo Nordisk A/S (“Novo Nordisk”). Specifically, Defendants failed to disclose that Hims was selling and deceptively promoting knockoff versions of weight-loss drug Wegovy, which created a substantial risk that the Company’s partnership with Novo Nordisk would be terminated.